A preliminary report on the use of Staphage Lysate for treatment of hidradenitis suppurativa.
Eight patients, 7 with hidradenitis suppurativa and 1 with chronic recurrent staphylococcal abscess, all of whom failed to respond to antibiotic therapy, conservative therapeutic measures, and surgery, were experimentally placed on Staphage Lysate. Treatment after appropriate skin testing consisted of subcutaneous infections of 0.1 ml and intranasal installation of 0.3 ml of Staphage Lysate. Treatments were weekly for twelve weeks, biweekly for six months, and then monthly. Complications, which occurred early, were minimal and involved rash, vertigo, malaise, chills, nausea, fever, and headache. Six of the 8 patients reported noticeable improvement in odor, consistency, and amount of drainage and considerable decreases in pain. Seven of the 8 patients reported improvement in the ability of lesions to drain spontaneously, and a decrease in the frequency of inflammatory nodules. All 8 patients reported that the inflammatory periods were definitely shorter. Early data suggests that Staphage Lysate is a useful adjuvant in the treatment of hidradenitis suppurativa.
D000038:Abscess / Q000628:therapy; D001050:Apocrine Glands; D001430:Bacteriocins / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation; D013203:Staphylococcal Infections / Q000628:therapy; D013543:Sweat Gland Diseases / Q000628:therapy*
D001430:Bacteriocins; C030591:staphage lysate